- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-4598
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Overcoming cisplatin resistance by mTOR inhibitor in lung cancer ; volume:4 ; number:1 ; day:20 ; month:7 ; year:2005 ; pages:1-10 ; date:12.2005
Molecular cancer ; 4, Heft 1 (20.7.2005), 1-10, 12.2005
- Creator
-
Wu, Chunjing
Wangpaichitr, Medhi
Feun, Lynn
Kuo, Marcus Tien
Robles, Carlos
Lampidis, Theodore
Savaraj, Niramol
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/1476-4598-4-25
- URN
-
urn:nbn:de:101:1-2021081521175439658202
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wu, Chunjing
- Wangpaichitr, Medhi
- Feun, Lynn
- Kuo, Marcus Tien
- Robles, Carlos
- Lampidis, Theodore
- Savaraj, Niramol
- SpringerLink (Online service)
Other Objects (12)
Overcoming Cisplatin Resistance in Pancreatic Cancer
Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)
The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma
Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer
Deptor: not only a mTOR inhibitor
mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
Combination therapy based on dual-target biomimetic nano-delivery system for overcoming cisplatin resistance in hepatocellular carcinoma
Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors
mTor Inhibitors for the Treatment of Endometriosis
mTOR inhibitors as radiosensitizers in neuroendocrine neoplasms
Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor
Overcoming Cisplatin Resistance in Pancreatic Cancer
Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)
The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma
Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer
Deptor: not only a mTOR inhibitor
mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
Combination therapy based on dual-target biomimetic nano-delivery system for overcoming cisplatin resistance in hepatocellular carcinoma
Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors
mTor Inhibitors for the Treatment of Endometriosis
mTOR inhibitors as radiosensitizers in neuroendocrine neoplasms
Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor
Overcoming Cisplatin Resistance in Pancreatic Cancer
Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)
The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma
Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer
Deptor: not only a mTOR inhibitor
mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
Combination therapy based on dual-target biomimetic nano-delivery system for overcoming cisplatin resistance in hepatocellular carcinoma
Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors
mTor Inhibitors for the Treatment of Endometriosis
mTOR inhibitors as radiosensitizers in neuroendocrine neoplasms